CN Patent

CN108653222A — 一种帕博西尼片剂组合物

Assigned to Weihai Guanbiao Information Technology Co Ltd · Expires 2018-10-16 · 8y expired

What this patent protects

本发明涉及一种帕博西尼(Palbociclib)片剂组合物，属于制药技术领域。本发明所述帕博西尼片剂，单位剂量的片剂中，含有D90为20‑40微米的帕博西尼75‑125mg，气相二氧化硅38‑60mg，琥珀酸16‑25mg，乳糖20‑36mg，十二烷基硫酸钠0.8‑1.8mg，交联聚维酮16‑24mg，硬脂酸镁1.6‑2.8mg。本发明技术方案获得了一种合格的片剂。

USPTO Abstract

本发明涉及一种帕博西尼(Palbociclib)片剂组合物，属于制药技术领域。本发明所述帕博西尼片剂，单位剂量的片剂中，含有D90为20‑40微米的帕博西尼75‑125mg，气相二氧化硅38‑60mg，琥珀酸16‑25mg，乳糖20‑36mg，十二烷基硫酸钠0.8‑1.8mg，交联聚维酮16‑24mg，硬脂酸镁1.6‑2.8mg。本发明技术方案获得了一种合格的片剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN108653222A
Jurisdiction
CN
Classification
—
Expires
2018-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Weihai Guanbiao Information Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.